Advanced Gastric Carcinoma - Pipeline Insight, 2024

This “Advanced Gastric Carcinoma - Pipeline Insight, 2024,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Gastric Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Advanced Gastric Carcinoma Understanding

Advanced Gastric Carcinoma: Overview

Advanced stomach cancer means that a cancer that began in the stomach has spread to at least one other part of the body, such as the liver or lungs. Stomach cancer can spread to the: liver, lungs, lymph nodes, and tissue lining the abdominal cavity (peritoneum). The symptoms of advanced stomach cancer depend on what part of the body the cancer has spread to. The most common symptoms of stomach cancer include: unexplained weight loss, feeling and being sick, stomach pain, difficulty swallowing, feeling tired. Advanced stage means your stomach cancer has spread. External radiotherapy can help to control your cancer and reduce symptoms. Treatments such as chemotherapy or radiotherapy or targeted drugs can sometimes help to reduce symptoms. Other treatments such as laser therapy or stents can treat a blockage in the stomach. Surgery can help relieve symptoms of advanced stomach cancer if your cancer is causing a blockage. Laser therapy uses hot beams of light to burn away cancer cells. This can help control symptoms of advanced stomach cancer.

Advanced Gastric Carcinoma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Gastric Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Gastric Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Gastric Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Gastric Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Gastric Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Gastric Carcinoma.

Advanced Gastric Carcinoma Emerging Drugs Chapters

This segment of the Advanced Gastric Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Gastric Carcinoma Emerging Drugs

Camrelizumab: Jiangsu Hengrui Medicine Camrelizumab (formerly known as HR 301210, INCSHR 1210, SHR 1210) is a humanised high-affinity IgG4-kappa monoclonal antibody that targets the programmed cell death-1 receptor. Currently, it is in Phase III stage of clinical trial evaluation to treat advanced gastric or gastroesophageal junctionadenocarcinoma.

Pamiparib: Bei GenePamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumormalignancies.

Advanced Gastric Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Gastric Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced Gastric Carcinoma

There are approx. 50+ key companies which are developing the therapies for Advanced Gastric Carcinoma. The companies which have their Advanced Gastric Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Jiangsu Hengrui Medicine.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Advanced Gastric Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Gastric Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Gastric Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Gastric Carcinoma drugs.

Advanced Gastric Carcinoma Report Insights

• Advanced Gastric Carcinoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Advanced Gastric Carcinoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Advanced Gastric Carcinoma drugs?
• How many Advanced Gastric Carcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Gastric Carcinoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Advanced Gastric Carcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Advanced Gastric Carcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Jiangsu Hengrui Medicine
• BeiGene
• CSPC ZhongQi Pharmaceutical Technology
• Linton PharmCo.,Ltd.
• Bristol-Myers Squibb
• Hanmi Pharmaceutical
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Idience Co., Ltd.
• Shanghai Henlius Biotech
• AstraZeneca
• Nanjing Legend Biotech Co.
• ALX Oncology Inc.
• Jiangsu Alphamab Biopharmaceuticals Co., Ltd
• Genentech
• Innovent Biologics (Suzhou) Co. Ltd.
• Qilu Pharmaceutical Co., Ltd.
• Next Cure,Inc.
• Chengdu Kanghong Biotech Co., Ltd.
• Gene Quantum Healthcare (Suzhou) Co.,Ltd.
• Janssen Pharmaceutical K.K.
• Shanghai Miracogen Inc.
• Ambrx, Inc.
• Imugene Limited
• Vedanta Biosciences, Inc.
• Celon Pharma SA
• Bicycle Tx Limited
• Seagen Inc.

Key Products

• Camrelizumab
• Pamiparib
• Mitoxantrone Hydrochloride Liposome
• Catumaxomab
• Ipilimumab
• Relatlimab
• FLX475
• DP303c
• IDX-1197
• HLX22
• Olaparib
• LCAR-C18S
• ALX148
• KN026
• Atezolizumab
• Sintilimab
• QL1604
• NC410
• KH903
• GQ1001
• Amivantamab
• IMU-131
• BT8009
• VE800
• CPL304110
• ARX788
• MRG002
• SEA-TGT

This product will be delivered within 2-4 business days.